Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 1,671 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Comparator Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of SBS-147 in Healthy Adults

NCT07335913
View directory record Official record
Conditions
Pain Acute, Pain
Interventions
SBS-147, Placebo
Drug
Lead sponsor
Sparian Biosciences, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

DAILIES TOTAL1 Versus ACUVUE TruEye - Effects on the Biology of the Ocular Surface and Lid Margin

NCT02347631
View directory record Official record
Conditions
Soft Contact Lenses, Myopia
Interventions
Soft Contact Lens - Daily Disposable Alcon Dailies Total 1 and ACUVUE TruEye, Soft Contact Lens - Acuvue TruEye and Alcon DAILIES TOTAL 1.
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 38 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Phase 4 Interventional Results available

Effect of Vyvanse on Driving in Young Adults With ADHD

NCT00801229
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder(ADHD)
Interventions
Vyvanse, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 24 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss

NCT02345031
View directory record Official record
Conditions
Age-Related Hearing Loss
Interventions
AUT00063, Placebo
Drug
Lead sponsor
Autifony Therapeutics Limited
Industry
Eligibility
50 Years to 89 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Sacramento, California • Colorado Springs, Colorado • Boca Raton, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Phase 2 Interventional

A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy

NCT00424931
View directory record Official record
Conditions
Narcolepsy
Interventions
JNJ-17216498, Modafinil
Drug
Lead sponsor
Alza Corporation, DE, USA
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Phase 4 Interventional Results available

Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

NCT00351611
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Lyrica (pregabalin), placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
103
States / cities
Mobile, Alabama • Northport, Alabama • Tuscaloosa, Alabama + 57 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Assessment of DHA On Reducing Early Preterm Birth

NCT02626299
View directory record Official record
Conditions
Preterm Birth
Interventions
Docosahexaenoic acid - 800mg/day, Docosahexaenoic acid - 200mg/day, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

NCT00696436
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil, Valsartan, Olmesartan, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
86
States / cities
Alabaster, Alabama • Ozark, Alabama • Green Valley, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Phase 4 Interventional Results available

A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis

NCT01916226
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial and Seasonal
Interventions
FPNS, FPNS Placebo, Cetirizine, Cetirizine Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
31
States / cities
Little Rock, Arkansas • Denver, Colorado • Aventura, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Not applicable Interventional Results available

Nicotine Withdrawal Symptoms and Smoking Relapse

NCT01511614
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Transcranial Direct Current Stimulation, sham, Nicotine patch, Placebo patch, Varenicline Pill, Placebo pill, Motivational Interviewing
Device · Drug · Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers

NCT02691702
View directory record Official record
Conditions
Healthy Adult Subjects, Healthy Elderly Subjects
Interventions
BIIB118, Melatonin
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 85 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

RCT of a Polyherbal Dietary Supplement for Prediabetes

NCT03388762
View directory record Official record
Conditions
Prediabetic State
Interventions
GlucoSupreme™ Herbal, Placebo
Dietary Supplement · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
4
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

NCT05696080
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
V116, Placebo, PCV15, PPSV23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
518 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
8
States / cities
Mesa, Arizona • Hialeah, Florida • West Palm Beach, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 28, 2026, 5:37 AM EDT
Recruiting Phase 2 Interventional

Oxytocin Effects on Bone in Children With Autism Spectrum Disorder

NCT05754073
View directory record Official record
Conditions
Autism Spectrum Disorder, Bone Health
Interventions
1. Intranasal oxytocin spray, 2. Intranasal placebo spray, 3. Intranasal Oxytocin spray
Drug
Lead sponsor
Elizabeth Austen Lawson
Other
Eligibility
6 Years to 18 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Phase 3 Interventional

Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris

NCT02865005
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Dapsone 5.0% Gel (SEEGPharm), Placebo, Dapsone 5.0% Gel (Allergan)
Drug · Other
Lead sponsor
Seegpharm S.A.
Industry
Eligibility
12 Years to 40 Years
Enrollment
2,361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
35
States / cities
Encino, California • Fullerton, California • La Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 28, 2026, 5:37 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

NCT06719141
View directory record Official record
Conditions
Developmental and Epileptic Encephalopathy
Interventions
LP352, Placebo
Drug
Lead sponsor
Longboard Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
31
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 28, 2026, 5:37 AM EDT
Not yet recruiting Not applicable Interventional

Dissemination Of Lung Cancer Screening Education Through Tobacco Quitlines

NCT07720141
View directory record Official record
Conditions
Lung Cancer
Interventions
High-touch strategy
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2034
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Phase 3 Interventional Results available

To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways

NCT02085161
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
placebo to tiotropium + olodaterol, tiotropium +olodaterol, tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
San Diego, California • Torrance, California • Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Phase 2 Interventional Results available

BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

NCT02337907
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Placebo, BI 409306, Donepezil
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
55 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Sherman Oaks, California • Orlando, Florida • West Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single Ascending Dose Study of AMG 570 in Healthy Subjects

NCT02618967
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
AMG 570, AMG 570 Matching Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
3
States / cities
Evansville, Indiana • Overland Park, Kansas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Phase 2 Interventional

FP-101 for the Treatment of Hot Flashes in Postmenopausal Women

NCT03285672
View directory record Official record
Conditions
Hot Flashes
Interventions
FP-101, Placebo Comparator
Drug
Lead sponsor
Fervent Pharmaceuticals
Industry
Eligibility
40 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
12
States / cities
Champaign, Illinois • Cary, North Carolina • Charlotte, North Carolina + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Oct 28, 2026, 5:37 AM EDT
Terminated Phase 4 Interventional Results available

Does IV Ondansetron Prevent Pruritus After Intrathecal Morphine in Pediatric Patients?

NCT03262038
View directory record Official record
Conditions
Pruritus, Nausea/Vomiting
Interventions
Ondansetron, Placebo Comparator
Drug
Lead sponsor
University of Michigan
Other
Eligibility
3 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

NCT02346240
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Etanercept, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
19
States / cities
Mobile, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 28, 2026, 5:37 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)

NCT00624338
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Atacicept 75 mg, Atacicept 150 mg, Placebo Comparator
Drug · Other
Lead sponsor
EMD Serono
Industry
Eligibility
16 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
18
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 28, 2026, 5:37 AM EDT